Table 2.
Other Correlation of KYNU expression with BC clinicopathologic characteristics
| Characteristic | KYNU expression | P‐value | |
|---|---|---|---|
| Low expression No. (%) | High expression No. (%) | ||
| Age (y)* | 51 (36‐73) | 49 (35‐84) | .56 |
| N‐stage | |||
| N0 | 23/111 (20.7%) | 22/111 (19.8%) | .422 |
| N1 | 21/111 (18.9%) | 22/111 (19.8%) | |
| N2 | 10/111 (9.0%) | 7/111 (6.3%) | |
| N3 | 5/111 (4.5%) | 1/111 (0.90%) | |
| Oestrogen receptor | |||
| Positive | 34/134 (25.4%) | 54/134 (40.3%) | .002 |
| Negative | 31/134 (23.1%) | 15/134 (11.2%) | |
| Progesterone receptor | |||
| Positive | 28/126 (22.2%) | 41/126 (32.5%) | .007 |
| Negative | 37/126 (29.4%) | 20/126 (15.9%) | |
| HER‐2 | |||
| Positive | 40/99 (40.4%) | 30/99 (30.3%) | .04 |
| Negative | 10/99 (10.1%) | 19/99 (19.2%) | |
| E‐cad | |||
| ≥50% | 9/78 (11.6%) | 16/78 (20.5%) | .03 |
| <50% | 33/78 (42.3%) | 20/78 (25.6%) | |
| Ki‐67 | |||
| ≥15% | 38/97 (39.2%) | 25/97 (25.8%) | .019 |
| <15% | 12/97 (12.4%) | 22/97 (22.7%) | |
*
Median (range).